

Joint meeting of the
International Union of Basic and Clinical Pharmacology (IUPHAR)
2014-2018 and 2018-2022 Executive Committees

Minutes

July 5th at 11:30 a.m. and July 6th at 1:30 p.m., 2018
Room 103, Kyoto International Conference Center (KICC), Japan

#Participants

2014-2018 Executive Committee

S. J. Enna, USA, President
Graeme Henderson, United Kingdom, First Vice President
Masamitsu Iino, Japan, Second Vice President
David LeCouteur, Australia, Clinical Division Secretary-General
Francesca Levi-Schaffer, Israel, Councilor
Maria Isabel Lucena, Spain, Clinical Division Treasurer
Eeva Moilanen, Finland, Councilor
Bhagirath Patel, India, Councilor
Michael Spedding, France, Secretary General
Petra Thürmann, Germany, Treasurer
David Webb, United Kingdom, Clinical Division Chair
Yong-Xiang Zhang, China, Councilor

2018-2022 Executive Committee Nominated Members

Ingolf Cascorbi, Germany, President
Guan-Hua Du, China, Councilor
S. J. Enna, USA, Past President
Yoshikatsu Kanai, Japan, Second Vice President
Michelle Tidwell, USA, Parthenon Management Group
Helen Ochuko Kwanashie, Nigeria, Councilor
David LeCouteur, Australia, Clinical Division Chair
Francesca Levi-Schaffer, Israel, First Vice President
Maria Isabel Lucena, Spain, Clinical Division Treasurer
Caroline Samer, Switzerland, Clinical Division Vice Chair
Michael Spedding, France, Secretary General
Guilherme Suarez-Kurtz, Brazil, Councilor
David Webb, United Kingdom, Councilor

IUPHAR Staff

Leigh Ann Arbuckle, USA, Treasurer's Assistant
Kristen Kovach, USA, Executive Officer
Lynn LeCount, USA, Administrative Officer
Michelle Tidwell, Parthenon Management Group

Unavailable

James Barrett, USA, Treasurer
Arthur Christopoulos, Australia, Councilor
Patrick du Souich, Canada, 2014 – 2018 Past President
Nilima A. Kshirsagar, India, Clinical Division Secretary General

Guest on July 6th

Mitsuhiro Yoshioka, Japan, Japanese Pharmacological Society President

Joint meeting of the 2014-2018 and 2018-2022 Executive Committees

Minutes

Page 2

1. President's welcome

The meeting was called to action at 11:34 am by Dr. Cascorbi. Dr. Cascorbi welcomed everyone as expressed gratitude at being elected to the role of President of IUPHAR. He thanked the incoming and outgoing executive committee and expressed individual thanks to Dr. Enna and Mrs. LeCount for their hard work and dedication to IUPHAR.

2. Secretary-General's comments

Dr. Spedding welcomed everyone and asked everyone to introduce themselves. After the introductions, Dr. Spedding discussed some upcoming issues to consider.

3. 2018-2022 Appointments

Dr. Spedding went through the business below that needed to be addressed. The committee accepted the nominations of NC-IUPHAR chair: Steve Alexander and of the Membership Committee, consisting of: Chair: John Miners and members: Jeff Aronson, Sinem Gülmez, Douglas Oliver and Diadelis Ramirez. The committee then discussed various strategies to expand the number of IUPHAR member societies. These included: helping PharfA expand their reach by assisting the creation of smaller societies in Africa and supporting the applications of smaller existing societies. They also discussed the importance of supporting the eleven new African clinical research centers and providing reduced membership fees to smaller societies. The officers agreed to set up a call with the Chair of the Membership Committee.

4. Congresses

a. WCP2026

WCP2026 was awarded to ASCEPT to hold the conference in Melbourne, Australia. The committee agreed to establish the finance committee for this congress. According the IUPHAR Statutes, for each WC a finance committee shall be established. The 2026 Finance committee will consist of Ingolf Cascorbi, Arthur Christopoulos, James Barrett (IUPHAR Treasurer), David LeCouteur, David Webb, Michael Spedding, Dom Geraghty, Carl Fitzpatrick, and Emilio Badoer. Francesca Levi-Schaffer, Helen Ochuko Kwanashie, and Guan-Ha Du will serve as consultants to the group on an as needed bases.

b. WCP2022

According to IUPHAR Statutes, the 2022 Finance Committee must be replaced by the International Advisory Board (IAB) and the committee agreed to this action. The IAB members are: IUPHAR Executive Officers, Caroline Samer, Arthur Christopoulos, and David Webb. The IAB can also include other members of BPS choosing, should they wish. WC2022 President, David Webb, reported that everything is going well for the conference. They have their budget set, as well as the hotels. They are working on final negotiations with the PCO and should have that finalized shortly. Advertising will begin in late July for this meeting.

c. WCP2018

The President of WC2018, Masamitsu Iino, gave a brief report of the congress outcomes. He reported that the congress was promoted in many different countries and that the registration included 4,355 individuals as of 7/4/18. They were able to secure 3 top sponsors, 4 gold level, and 9 silver level sponsors. The congress is expected to make a profit, which will be split with IUPHAR. Approximately 55% of the attendees were from Japan. It was agreed that the WC2018 was a great success.

5. Update on the Japanese Pharmacological Society (JPS)

Dr. Cascorbi thanked the JPS for making the WC2018 a success. Dr. Kanai gave an overview of the society starting with stating that it was established in 1927. He went on to say that the number of young researchers in the field is decreasing and there is a need for

Joint meeting of the 2014-2018 and 2018-2022 Executive Committees

Minutes

Page 3

more educational programs with linkages to other related disciplines. There is also more need for linkages between societies. JPS uses its website to provide educational tools and resources for its users. It was stated that the JPS has been very generous supporting PEP in the last 3 years and that IUPHAR needs to have more interaction with the JPS. It was stated that the BPS held a symposium about difficulties recruiting new people into the discipline and are going to ask young researchers what they are looking for from pharmacology as a discipline. BPS will share the results of these surveys. IUPHAR's Secretary General thanked JPS for paying for Japanese scientists to attend NC IUPHAR meetings on a regular basis. IUPHAR and NC-IUPHAR works to foster more open innovation. It was stated that the discipline should work on marketing and rebranding pharmacology to increase young scientists' interests in pharmacology. Pharmacology is the science of understanding of drug action, drug discovery and development and is open to new concepts and paradigms. There are many possibilities for new targets and new methods. However, students do not have a clear career path in pharmacology and that creates unease about their future career trajectory. MS stated that the extension into immunopharmacology (www.guidetoinmunopharmacology.org) and the Memorandum of Understanding between the International Union of Immunopharmacology is a major step in this direction to extend the scope of pharmacology. The group further discussed the current state of education in pharmacology and some ideas on how to move the discipline forward. JPS stated that there have been 2,700 publications and 800 clinical trials conducted in Japan and the JCP covers the clinical trials that occur in Japan. In addition, there are six local groups that encourage young people to study abroad so that they can improve their education in drug development. JPS stated that the system to become a medical doctor has dramatically changed in Japan in recent years to include more training and this has caused young people to continue their training in pharmacology at lower rates. It was stated that similar issues are occurring everywhere and it is difficult to approach this problem. One idea is to create a database of MDs who are running clinical trials and offer transverse training so that they would think of themselves as clinical pharmacologists. Pharmacology needs to work more to create bridges between specialties. JPS likes these ideas and would be interested in working on them with IUPHAR and stated it would be helpful to create a committee. Dr. Spedding will work to set up a monthly phone conversation with JPS.

6. Treasurer's report

IUPHAR Treasurer, Petra Thürmann, presented the 4-year budget for IUPHAR and stated that although the society income is stable, however, the same cannot be said about donation income. IUPHAR might be able to break even if the society gets more donations. The travel costs can make expenses increase as well. The committee agreed that there should be an increase in expenses in the budget to cover the Secretary General's expenses (will increase to \$5,000/year). In addition the notary expenses should be increased to \$5,000 for 2018 and the external audit should increase to \$8,700 for 2018. The committee put forth a motion to continue being a paying member of ICLAS and that motion was approved. The committee unanimously voted to approve the 2018-2021 budget with the aforementioned changes. The committee discussed the need to set up a different bank account so that US-based individuals associated with IUPHAR could make banking transactions. Parthenon Management Group (PMG) is working to set up a second bank account and when that is complete the treasurer will transfer €30,000 to the new account. The committee also agreed that the President, Treasurer, Secretary General, and President of Parthenon Management Group will be signatories on the IUPHAR bank accounts.

7. Overview of activity reports (M. Spedding)

- a. Nomenclature Committee (NC-IUPHAR). Steve Alexander was confirmed as the chair of the committee and Dr. Kanai of JPS has contributed much to the meetings and to the database. The committee has contacted the Gates Foundation to talk

Joint meeting of the 2014-2018 and 2018-2022 Executive Committees

Minutes

Page 4

about potential future funding. The Guide to Pharmacology previously received money for all targets, but the grant funding ends in October. This directly affects the employment of one person. The Wellcome Trust grant is sponsoring a meeting on Immunopharmacology in Edinburgh in October which will launch the Guide to Immunopharmacology. The database for drug discovery with medicines for malaria with all drug targets will be finished by the mid-2019. Dr. Spedding thanked BPS who supports two database curators for the Guide to Pharmacology, the BPS publication, the Concise Guide to Pharmacology and for all their support to NC-IUPHAR.

- b. Division of Clinical Pharmacology The current chair Dr. Webb reported officers of the division and its subcommittees. He stated that they have been productive and have had a busy year.

- i. Subcommittee of Clinical Pharmacology in Developing Countries (the outgoing chair is Lars. Gustafsson and Olayinke Ogunleye is elected as new chair) Dr. Ogunleye began the subcommittee overview by thanking the IUPHAR leadership for their support of the committee. It was reported that the subcommittee began expanding their scope to make global clinical pharmacology its initiative. It is critical that they work to improve the capabilities surrounding clinical pharmacology in developing countries. The first step is to reach out to colleagues and work on prioritizing critical areas of need in research and education to confront problems in medicine. The subcommittee hopes to establish a drug information system for use across Africa for providers. The subcommittee would also like to work with the Clinical Division and PharfA to establish more training in clinical pharmacology. The subcommittee was able to hold a meeting in Nigeria to train people to do appropriate drug research. The attendance for this training was good-15 people attended (previously there were only 30 people trained in all of Nigeria). The subcommittee has been working to establish national societies in clinical pharmacology and have been able to form a national society in Nigeria.
- ii. Subcommittee for Geriatric Clinical Pharmacology (Chair: S. Hilmer)
- iii. Subcommittee for Pharmacoepidemiology and Pharmacovigilance (Chair: M. Drici/ N. Buckley elected)

c. Sections

- i. Drug Metabolism and Drug Transport Section (Chair: A. Daly / M. Schwab elected)
- ii. Education Section (Outgoing Chair: Simon Maxwell, Elizabeth. Davis elected as new chair)
The outgoing chair provided an overview of the section's accomplishments during the past year starting with a brief discussion on the education section/Chinese collaboration. This is a reboot of the education program in China. Currently, there is \$10,000 in encumbered funds for clinical pharmacology in China.
 1. IOSP initiative (Chair: D. Lewis). The current chair is very motivated has many projects going around the world.
 2. Pharmacology Education Project (Chair: J. Szarek)
The funding for the PEP project will end in mid-2019. Current funds support a half position in Edinburgh through mid-2019. The division needs to carefully track the amount of money designated for this program so that they can determine the exact length of time for this position in conjunction with Pr Jamie Davies of Edinburgh. The division and IUPHAR also need to determine how to support the PEP project long term. The project is now getting praise and recognition and it is imperative that it continues to be supported.

Joint meeting of the 2014-2018 and 2018-2022 Executive Committees

Minutes

Page 5

ASPET initiated the support and the Chinese, the Japanese and the Hungarian societies have supported it.

- iii. *Gastrointestinal Pharmacology Section* (Outgoing Chair: D. Chen: K. Gyires elected)
- iv. *ImmuPhar (Immunopharmacology) Section* (Chair: F. Levi-Schaffer)
It was reported that the section, and IUPHAR established a MOU with the International Union of Immunological Sciences. Immunopharmacology has progressed massively recently with check-point inhibitors being used for cancer (1,024 clinical trials). The website is financed by Wellcome Trust (3-year grant which terminates in November) and there is a new committee between IUIS and the ImmuPhar section. The main purpose of this committee will be to recommend immunopharmacology protocols that will be key to help developing countries get a jump-start. The natural products meeting is also a major issue for this section as natural products have many immunological actions which are poorly characterized.
- v. *Natural Products Section* (Chair: Yongxiang Zhang)
This section has elected new members. The section was asked to make a presentation at a May 2018 conference. 300 people attended and it was very successful. The 2017 Aberdeen IUPHAR Natural Products meeting was a joint collaboration with ICMAN and IUPHAR. The section is currently working on the Natural Products Database Project. It is part of the Guide to Pharmacology. There were many exciting presentations for WCP2018 and the section plans to add corresponding members to enlarge its worldwide representation.
- vi. *Neuropsychopharmacology Section* (Chair: F. Drago), had made excellent progress with several key publications.
- vii. *Pediatric Clinical Pharmacology* (Chair: G. Kearns /F. Garcia-Bourniss elected)
The GRIP Project has been completed and there has not been a recent update. There has been a new chair elected and should have more activity this year.
- viii. *Pharmacogenetics/genomics Section* (Chair: G. Suarez-Kurtz / A. Somogyi elected)
The section held a business meeting and only seven people attended. Due to the expected low number of participants, it was decided to vote online before WCP2018. The result of the elections was approved by the participants of the business meeting.
- ix. *Editorial Board* (Chair: E. Ohlstein)
There have been 55 publications since 2014. Original NC-IUPHAR nomenclature papers are published in Pharmacological Reviews and more general NC-IUPHAR articles in British Journal of Pharmacology. BPS supports two people in the Edinburgh database group, which also produces the Concise Guide to Pharmacology. Most original publications come from NC-IUPHAR and the board would like to encourage all sections to publish via IUPHAR to raise the awareness of IUPHAR's projects. The board is discussing an IUPHAR linked journal as a potential funding stream. They are working with BPS and ASPET to make sure the journal would not interfere with any previous agreements. The committee requested that the rules for publishing under IUPHAR be distributed widely so more researchers understand the process.
- x. *Pharmacology for Africa* (Chair: D. Oliver)
The section currently participates in three monthly phone calls and the meeting in Kyoto went very well. The section worked to identify past challenges including the website, funding and structure of the section. The

Joint meeting of the 2014-2018 and 2018-2022 Executive Committees

Minutes

Page 6

section would like to explore registration as a charity. The section plans to be more organized moving forward and requests the continued strong support of IUPHAR.

8. Co-opted Members

The committee discussed the possibility of bringing on co-opted members to get more involvement from societies not represented on the Executive Committee. The members would ideally help IUPHAR with projects and serve as an advocate for the union. It would be an honorary position and would not carry travel or voting rights. The committee discussed that adding co-opted members should be done strategically and according to IUPHAR's greatest areas of need. The committee voted to add two co-opted members to the Executive Committee namely Dr. Bhagirath Patel, India and Dr. Emilio Clementi, Italy. They will serve four-year terms.

9. 2018-2022 Strategic Planning Meeting

Seven societies (ASCEPT, ASPET, BPS, CNPHARS, IPS, JPS, SIF). met and shared top priorities with IUPHAR leadership. The group agreed that IUPHAR should put together a strategic plan to incorporate the ideas from the member societies. This allows for more interaction with member societies and gets them involved in projects from the start of them. When IUPHAR has a strategic plan in place, some societies might be better able to support IUPHAR. IUPHAR also should have a governance review since its last review was several years ago. PMG, IUPHAR's management group, can help create the strategic plan and governance review and will put forth a proposal. The committee members discussed creating a new committee to work on these issues.

10. Meeting follow-up

- a. Dr. Barrett will communicate to the publisher proposing an affiliation with IUPHAR the issues raised during the Executive Committee meeting concerning the terms of any agreement. *(update by M. Spedding)*
- b. Dr. Barrett will draft a proposal to clarify the mission and goals of an IUPHAR Section on Academic Drug Discovery that will be used to obtain comments and suggestions, and to gauge the level of enthusiasm, of those working in this field. *(update by M. Spedding)*
- c. Drs. Henderson, Iino, LeCouteur, Spedding and Zhang will explore potential roles and tasks that could be assigned to a Beijing branch office of IUPHAR. *(update by M. Spedding)*
- d. Dr. Spedding will circulate to the 2014-2018 Executive Committee members a revised position description of co-opted members so a recommendation may be made to the 2018-2022 Executive Committee members in Kyoto. *(update by M. Spedding)*
- e. Corresponding Member appointments
- f. Young Investigator Corresponding Member nominations
 - a. Description
 - b. Ranking form to be completed in advance
 - c. Nomination packages

11. Next Executive Committee meetings

The next Executive Committee meeting will be in Hyderabad, India in conjunction with the 2019 IUPHAR World Conference on the Pharmacology of Natural and Traditional Medicines, jointly organized by the IUPHAR Pharmacology of Natural Products Section and the Indian Pharmacological Society during their Annual Meeting on 4-7 December 2019. Dr. Kumar encouraged everyone to attend and reported that they are getting support from many corporations. The IPS expects around 2-3,000 people to attend. The conference will be held in a 100 year-old venue and will have government funding. IPS is

Joint meeting of the 2014-2018 and 2018-2022 Executive Committees

Minutes


Page 7

working on drafting a 2019 action plan and expects it to be a critical action year for the society.

12. Other Business / Closing Remarks

The committee members were thanked for their participation and the meeting was adjourned at 5:42 p.m. on 6 July 2018.

Approved by:


S.J. Enna, IUPHAR Immediate Past President

Date:

8/30/18

Approved by:


Michael Spedding, IUPHAR Secretary General

Date:

9/3/2018